Biopharma Sentiment Index climbs to upbeat 105 in Q3 2026, marking strongest optimism in years

Endpoints Signal released its Q3 2026 Biopharma Sentiment Index, showing a dramatic lift in industry mood. The survey indicates the sector is finally in a positive territory after a four-year downturn.

The headline score jumped to 105, up from 96 in the prior quarter, crossing the 100 mark that signals an upbeat outlook.

Sentiment improved across all ten survey measures, which cover business conditions, company finances, funding climate, regulation and hiring.

A few respondents warned of early signs of speculative bubbles, especially in deal-making activity and AI investments.

The index is a global benchmark that surveys biopharma professionals each quarter to track these core areas.